Alliance for Pandemic Preparedness

October 15, 2020

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Category:

Topic:

Keywords (Tags):

  • In an ongoing randomized controlled phase 1 trial of RNA-vaccine candidates BNT162b1 and BNT162b2 (n=195), both vaccine candidates elicited similar dose-dependent SARS-CoV-2 neutralizing titers, which were similar to titers of a panel of SARS-CoV-2 convalescent serum samples. BNT162b2 was associated with a lower incidence and severity of systemic reactions than BNT162b1, particularly in older adults, supporting its selection for advancement to phase 2-3 evaluations.

Walsh et al. (Oct 14, 2020). Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2027906